keyword
https://read.qxmd.com/read/38469236/impact-of-oseltamivir-on-the-risk-of-cancer
#1
JOURNAL ARTICLE
Pei-Hua Chuang, Bor-Show Tzang, Chih-Chen Tzang, Chun-Ching Chiu, Chun-Yu Lin, Tsai-Ching Hsu
PURPOSE: Mounting evidence has revealed the anti-cancer activity of various anti-viral drugs. Oseltamivir phosphate (OP), namely Tamiflu® , is routinely used to combat influenza infections. Although evidence has indicated the anti-cancer effects of OP in vitro and in vivo , little information is known about the effect of OP use on cancers in humans. METHODS: A nationwide population-based cohort study involving 13,977,101 cases with 284,733 receiving OP was performed to examine the association between OP use and cancers using the National Health Insurance Research Database in Taiwan between 2009 and 2018...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38354825/effectiveness-of-oseltamivir-in-reducing-covid-19-related-in-hospital-deaths-a-pharmacoepidemiologic-study
#2
JOURNAL ARTICLE
Char Leung, Li Su, Lucy Taylor, Eduardo Araújo Oliveira, Ana Cristina Simões E Silva
BACKGROUND: Oseltamivir, as a low-cost antiviral agent, may support or complement treatment of COVID-19. This study assessed whether oseltamivir is effective in reducing COVID-19 related mortality. METHODS: This retrospective cohort study investigated real world data from a nationwide database of hospitalization due to severe acute respiratory syndrome in Brazil. We used propensity score matching to mimic a randomized controlled trial with "oseltamivir" and "no antivirals at all" as the intervention and control groups, respectively...
February 12, 2024: International Journal of Antimicrobial Agents
https://read.qxmd.com/read/38350497/discovery-of-cyperenoic-acid-as-a-potent-and-novel-entry-inhibitor-of-influenza-a-virus
#3
JOURNAL ARTICLE
Xiaoli Zhang, Yiping Xia, Peibo Li, Zhongnan Wu, Ruilin Li, Jialiao Cai, Yubo Zhang, Guocai Wang, Yaolan Li, Wei Tang, Weiwei Su
Influenza therapeutics with new targets and modes of action are urgently needed due to the frequent emergence of mutants resistant to currently available anti-influenza drugs. Here we report the in vitro and in vivo anti-influenza A virus activities of cyperenoic acid, a natural compound, which was isolated from a Chinese medicine Croton crassifolius Geise. Cyperenoic acid could potently suppress H1N1, H3N2 and H9N2 virus replication with IC50 values ranging from 0.12 to 15.13 μM, and showed a low cytotoxicity against MDCK cells (CC50  = 939...
February 11, 2024: Antiviral Research
https://read.qxmd.com/read/38305261/antiviral-activity-of-some-compounds-of-gasteroid-mushrooms-from-western-siberia
#4
JOURNAL ARTICLE
Elena V Makarevich, Tamara V Teplyakova, Oleg Yu Mazurkov, Ekaterina I Filippova, Natalia A Mazurkova
The antiviral activity of aqueous and ethanol extracts from the fruiting bodies of gasteroid Basidiomy-cetes of Western Siberia: Lycoperdon pyriforme, Lycoperdon perlatum, and Phallus impudicus, as well as an aqueous extract from cultivated mycelium of P. impudicus and total polysaccharides from it, on MDCK cell culture against influenza A virus, was studied. Aqueous and ethanol extracts from the fruiting bodies of all studied gasteroid fungi showed antiviral activity against human influenza virus A/Aichi/2/68 (H3N2) and bird A/chicken/Kurgan/05/2005 virus (H5N1)...
2024: International Journal of Medicinal Mushrooms
https://read.qxmd.com/read/38211646/oseltamivir-phosphate-interaction-with-model-membranes
#5
JOURNAL ARTICLE
Adriána Čelková, Alexander Búcsi, Mária Klacsová, Tomáš Fazekaš, Juan Carlos Martínez, Daniela Uhríková
Oseltamivir belongs to the neuraminidase inhibitors, developed against the influenza virus, and registered under the trademark Tamiflu. Despite its long-term acquaintance, there is limited information in the literature about its physicochemical and structural properties in a lipid-water system. We present an experimentally determined partition coefficient with structural information on the interaction of oseltamivir with the model membrane, its possible location, and its effect on the membrane thermodynamics...
January 9, 2024: Biochimica et Biophysica Acta. Biomembranes
https://read.qxmd.com/read/38190441/structural-studies-of-inhibitors-with-clinically-relevant-influenza-endonuclease-variants
#6
JOURNAL ARTICLE
Alysia J Kohlbrand, Ryjul W Stokes, Banumathi Sankaran, Seth M Cohen
Vital to the treatment of influenza is the use of antivirals such as Oseltamivir (Tamiflu) and Zanamivir (Relenza); however, antiviral resistance is becoming an increasing problem for these therapeutics. The RNA-dependent RNA polymerase acidic N-terminal (PAN ) endonuclease, a critical component of influenza viral replication machinery, is an antiviral target that was recently validated with the approval of Baloxavir Marboxil (BXM). Despite its clinical success, BXM has demonstrated susceptibility to resistance mutations, specifically the I38T, E23K, and A36 V mutants of PAN ...
January 8, 2024: Biochemistry
https://read.qxmd.com/read/37935021/comparison-chart-antiviral-drugs-for-influenza-for-2023-2024
#7
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 13, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/37935018/antiviral-drugs-for-influenza-for-2023-2024
#8
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 13, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/37871115/influenza-vaccine-for-2023-2024
#9
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
October 16, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/37722683/viral-interference-during-influenza-a-sars-cov-2-coinfection-of-the-human-airway-epithelium-and-reversal-by-oseltamivir
#10
JOURNAL ARTICLE
Nagarjuna R Cheemarla, Timothy A Watkins, Valia T Mihaylova, Ellen F Foxman
To gain insight into interactions among respiratory viruses, we modeled influenza A virus (IAV) - SARS-CoV-2 coinfections using differentiated human airway epithelial cultures. Replicating IAV induced a more robust interferon response than SARS-CoV-2 and suppressed SARS-CoV-2 replication in both sequential and simultaneous infections, whereas SARS-CoV-2 did not enhance host cell defense during influenza infection or suppress IAV replication. Oseltamivir, an antiviral targeting influenza, reduced IAV replication during coinfection but also reduced the host antiviral response and restored SARS-CoV-2 replication...
September 18, 2023: Journal of Infectious Diseases
https://read.qxmd.com/read/37598506/microbial-engineering-for-shikimate-biosynthesis
#11
REVIEW
Qiang Ding, Chao Ye
Shikimate, a precursor to the antiviral drug oseltamivir (Tamiflu®), can influence aromatic metabolites and finds extensive use in antimicrobial, antitumor, and cardiovascular applications. Consequently, various strategies have been developed for chemical synthesis and plant extraction to enhance shikimate biosynthesis, potentially impacting environmental conditions, economic sustainability, and separation and purification processes. Microbial engineering has been developed as an environmentally friendly approach for shikimate biosynthesis...
August 15, 2023: Enzyme and Microbial Technology
https://read.qxmd.com/read/37562489/phytochemical-investigation-of-pistacia-lentiscus-l-var-chia-leaves-a-byproduct-with-antimicrobial-potential
#12
JOURNAL ARTICLE
Christodoulos Anagnostou, Stavros Beteinakis, Anastasia Papachristodoulou, Vasiliki K Pachi, Mariangela Dionysopoulou, Sofia Dimou, George Diallinas, Leandros A Skaltsounis, Maria Halabalaki
Pistacia lentiscus L. var. Chia belongs to the Anacardiaceae family, and it is cultivated only in the south part of Chios island, in Greece. Even though it is renowned for its unique resin, Chios mastic gum (CMG), the tree leaves have also been used in traditional medicine, while the annual pruning generates a large biomass of unused by-products. Thus, the aim of the present study was the detailed phytochemical investigation of P. lentiscus var. Chia leaves towards the search of antimicrobial agents. UPLC-HRMS & HRMS/MS based dereplication methods led to the detailed characterization of the aqueous leaf extract...
October 2023: Fitoterapia
https://read.qxmd.com/read/37367905/multiple-metabolic-engineering-strategies-to-improve-shikimate-titer-in-escherichia-coli
#13
JOURNAL ARTICLE
Taidong Bo, Chen Wu, Zeting Wang, Hao Jiang, Feiao Wang, Ning Chen, Yanjun Li
Shikimate is a valuable chiral precursor for synthesizing oseltamivir (Tamiflu® ) and other chemicals. High production of shikimate via microbial fermentation has attracted increasing attention to overcome the unstable and expensive supply of shikimate extracted from plant resources. The current cost of microbial production of shikimate via engineered strains is still unsatisfactory, and thus more metabolic strategies need to be investigated to further increase the production efficiency. In this study, we first constructed a shikimate E...
June 12, 2023: Metabolites
https://read.qxmd.com/read/37120995/conformationally-locked-sugar-derivatives-and-analogues-as-potential-neuraminidase-inhibitors
#14
REVIEW
Yogesh Yadav, Rajdeep Tyagi, Ramesh Kumar, Ram Sagar
The influenza virus remains a major health concern for mankind because it tends to mutate frequently and cause high morbidity. Influenza prevention and treatment are greatly aided by the use of antivirals. One such class of antivirals is neuraminidase inhibitors (NAIs), effective against influenza viruses. A neuraminidase on the virus's surface serves a vital function in viral propogation by assisting in the release of viruses from infected host cells. Neuraminidase inhibitors are the backbone in stoping such virus propagation thus helps in the treatment of influenza viruses infections...
April 24, 2023: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/36946567/fighting-the-flu-a-brief-review-on-anti-influenza-agents
#15
REVIEW
Sambuddha Chakraborty, Ashwini Chauhan
The influenza virus causes one of the most prevalent and lethal infectious viral diseases of the respiratory system; the disease progression varies from acute self-limiting mild fever to disease chronicity and death. Although both the preventive and treatment measures have been vital in protecting humans against seasonal epidemics or sporadic pandemics, there are several challenges to curb the influenza virus such as limited or poor cross-protection against circulating virus strains, moderate protection in immune-compromised patients, and rapid emergence of resistance...
March 22, 2023: Biotechnology & Genetic Engineering Reviews
https://read.qxmd.com/read/36810140/oseltamivir-phosphate-for-suspension-is-bioequivalent-to-tamiflu-in-healthy-volunteers-a-randomized-open-label-clinical-study
#16
JOURNAL ARTICLE
Ying Wang, Bangzhong Tang, Jing Xie, Xiaoqin Wang, Peng Ren, Guangmei Wu, Cuixia He, Minhui Zhu, Yue Su, Jiaxiang Ding, Yuanyuan Xu, Ling Fan, Qin Ge, Yuzhou Ding, Juan Zhu, Bingyan Liu, Rongfang Shan, Huan Zhou
PURPOSE: The study was aimed at evaluating the bioequivalence and safety of oseltamivir phosphate for suspension, provided by Shenzhen Beimei Pharmaceutical Co. Ltd. and manufactured by Hetero Labs Limited, and the reference product TAMIFLU® in healthy Chinese subjects. METHODS: A single-dose, randomized, two-phase, self-crossed model was adopted. Among 80 healthy subjects, 40 subjects in the fasting group and 40 subjects in the fed group. Subjects in the fasting group were randomized into two sequences according to the proportion of 1:1, each given 75 mg/12...
February 21, 2023: BMC Pharmacology & Toxicology
https://read.qxmd.com/read/36600043/antiviral-activity-of-technologically-processed-antibodies-to-cd4-receptor-against-influenza-infection
#17
JOURNAL ARTICLE
N V Petrova, A G Emelyanova, S A Tarasov, Е А Glubokova, N P Каrtashova
The antiviral activity of technologically processed antibodies to CD4 receptor was evaluated a model of sublethal A/California/04/2009 (H1N1)pdm09-induced influenza infection in female BALB/c mice. The technologically processed antibodies increased animal survival rate by 50% in comparison with the placebo group (p<0.05), which correlated with significant inhibition of virus replication in the lungs (p<0.05). The reference drug Tamiflu increased mouse survival rate (by 47%), decreased the virus titer in the lungs, and prevented body weight loss (p<0...
January 5, 2023: Bulletin of Experimental Biology and Medicine
https://read.qxmd.com/read/36464143/shikimic-acid-biosynthesis-in-microorganisms-current-status-and-future-direction
#18
REVIEW
Qi Sheng, Lingxin Yi, Bin Zhong, Xiaoyu Wu, Liming Liu, Bin Zhang
Shikimic acid (SA), a hydroaromatic natural product, is used as a chiral precursor for organic synthesis of oseltamivir (Tamiflu®, an antiviral drug). The process of microbial production of SA has recently undergone vigorous development. Particularly, the sustainable construction of recombinant Corynebacterium glutamicum (141.2 g/L) and Escherichia coli (87 g/L) laid a solid foundation for the microbial fermentation production of SA. However, its industrial application is restricted by limitations such as the lack of fermentation tests for industrial-scale and the requirement of growth-limiting factors, antibiotics, and inducers...
December 1, 2022: Biotechnology Advances
https://read.qxmd.com/read/36454880/systematic-review-and-meta-analysis-of-the-efficacy-and-safety-of-oseltamivir-tamiflu-in-the-treatment-of-coronavirus-disease-2019-covid-19
#19
JOURNAL ARTICLE
Basiru Aliyu, Yakubu Egigogo Raji, Hui-Yee Chee, Mui-Yun Wong, Zamberi Bin Sekawi
Efforts are ongoing by researchers globally to develop new drugs or repurpose existing ones for treating COVID-19. Thus, this led to the use of oseltamivir, an antiviral drug used for treating influenza A and B viruses, as a trial drug for COVID-19. However, available evidence from clinical studies has shown conflicting results on the effectiveness of oseltamivir in COVID-19 treatment. Therefore, this systematic review and meta-analysis was performed to assess the clinical safety and efficacy of oseltamivir for treating COVID-19...
2022: PloS One
https://read.qxmd.com/read/36397192/comparison-chart-antiviral-drugs-for-influenza-for-2022-2023
#20
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 28, 2022: Medical Letter on Drugs and Therapeutics
keyword
keyword
50702
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.